Spotlight on almotriptan in migraine

CNS Drugs

Volumn 16, Issue 7, 2002, Pages 501-507

  Keam, Susan J ^a   Goa, Karen L ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ENZYME INHIBITOR; FLUOXETINE; KETOCONAZOLE; LITHIUM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PROPRANOLOL; SUMATRIPTAN; VERAPAMIL;

AREA UNDER THE CURVE; ARTERY BLOOD FLOW; BONE PAIN; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; FACE PAIN; FATIGUE; HEADACHE; HUMAN; MIGRAINE; NAUSEA; PARESTHESIA; PATIENT SATISFACTION; PHARMACODYNAMICS; PHOTOPHOBIA; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; THORAX PAIN; VERTIGO; VOMITING;

EID: 0036303987     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216070-00006     Document Type: Review

References (36)

1. Pharmacological characterization of almotriptan: An indolic 5-HT receptor agonist for the treatment of migraine
2. Nuevas perspectivas en el tratamiento de la migrãna
3. The functional activity of eletriptan and other 5-HT(1B/1D) agonists at the human recombinant 5-HT(1B) and 5-HT(1D) receptors
4. Vascular effects of the new antimigraine agent almotriptan on human cranial and peripheral arteries
5. Functional profile of almotriptan in animal models predictive of antimigraine activity
6. Total plasma serotonin, 5-hydroxyindoleacefic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects
7. Oral pharmacokinetics of the new antimigraine agent almotriptan in young and elderly healthy volunteers
8. Efficacy of oral almotriptan, a novel 5-HT{-1B/D} agonist in migraine [poster]
9. A clinical trial to determine the lack of food interaction on the bioavailability of almotriptan, a new 5-HT1B/1D agonist, in healthy volunteers
10. Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers
11. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug
12. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug [poster]
13. Absolute bioavailability of oral and subcutaneous almotriptan
14. Pharmacokinetics of oral almotriptan during and outside a migraine attack
15. Metabolism of the novel anti-migraine compound almotriptan (LAS 31416) in humans
16. Almotriptan: Clinical profile
17. Almotriptan. Antimigraine 5-HT(1D/1B) agonist
18. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans
19. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers
20. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers
21. Effect of ketoconazole on the clearance of the antimigraine compound, almotriptan, in humans
22. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers
23. The pharmacokinetics and tolerability of almotriptan in renal impairment
24. Dose-finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine
25. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebo-controlled study
26. Equivalent efficacy of oral almotriptan, a new 5-HT{-1B/1D} agonist, compared with sumatriptan 100 mg
27. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison
28. A 6-month open-label study of orally administered almotriptan in migraine patients
29. Tolerability and efficacy of almotriptan in the long-term treatment of migraine
30. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan
31. Efficacy and tolerability of oral almotriptan in the treatment of migraine
32. Advantageous tolerability of almotriptan 12.5 mg compared with sumatriptan 100 mg
33. Cost savings in migraine associated with less chest pain on new triptan therapy